Avidicure to Present Preclinical Data from Lead TROP2-targeting Multifunctional Antibody Program at the 2025 American Society of Clinical Oncology Annual MeetingNovel TROP2-targeting AVC-Booster demonstrated prolonged and significantly improved tumor control in animal models, and activation of the full immune system in non-small cell lung cancer patient samples
Avidicure Launches with $50 Million in Seed Financing to Develop New Multifunctional Antibody Modality to Treat CancerAMSTERDAM, April 24, 2025 (GLOBE NEWSWIRE) -- Avidicure, a biotechnology company pioneering an entirely new multifunctional antibody modality with broad applicability in oncology, today announced its launch with a $50 million seed financing round, led by EQT Life Sciences with participation from Kurma Partners, BioGeneration Ventures, BOM, Curie Capital, and V-Bio Ventures.
